Max-Delbrück-Center for Molecular Medicine (MDC), Berlin, Germany.
Klinik für Viszeral-, Thorax- und Gefäßchirurgie, Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany.
Gut. 2016 Oct;65(10):1690-701. doi: 10.1136/gutjnl-2014-307900. Epub 2015 Jul 8.
We have previously identified a 115-gene signature that characterises the metastatic potential of human primary colon cancers. The signature included the canonical Wnt target gene BAMBI, which promoted experimental metastasis in mice. Here, we identified three new direct Wnt target genes from the signature, and studied their functions in epithelial-mesenchymal transition (EMT), cell migration and experimental metastasis.
We examined experimental liver metastases following injection of selected tumour cells into spleens of NOD/SCID mice. Molecular and cellular techniques were used to identify direct transcription target genes of Wnt/β-catenin signals. Microarray analyses and experiments that interfered with cell migration through inhibitors were performed to characterise downstream signalling systems.
Three new genes from the colorectal cancer (CRC) metastasis signature, BOP1, CKS2 and NFIL3, were identified as direct transcription targets of β-catenin/TCF4. Overexpression and knocking down of these genes in CRC cells promoted and inhibited, respectively, experimental metastasis in mice, EMT and cell motility in culture. Cell migration was repressed by interfering with distinct signalling systems through inhibitors of PI3K, JNK, p38 mitogen-activated protein kinase and/or mTOR. Gene expression profiling identified a series of migration-promoting genes, which were induced by BOP1, CKS2 and NFIL3, and could be repressed by inhibitors that are specific to these pathways.
We identified new direct Wnt/β-catenin target genes, BOP1, CKS2 and NFIL3, which induced EMT, cell migration and experimental metastasis of CRC cells. These genes crosstalk with different downstream signalling systems, and activate migration-promoting genes. These pathways and downstream genes may serve as therapeutic targets in the treatment of CRC metastasis.
我们之前已经鉴定出一个 115 个基因的特征签名,可描述人类原发性结肠癌的转移潜能。该签名包括经典 Wnt 靶基因 BAMBI,它可促进小鼠实验性转移。在此,我们从该签名中鉴定出三个新的直接 Wnt 靶基因,并研究它们在上皮-间充质转化(EMT)、细胞迁移和实验性转移中的功能。
我们研究了选定的肿瘤细胞注射到 NOD/SCID 小鼠脾脏后引起的实验性肝转移。采用分子和细胞技术来鉴定 Wnt/β-catenin 信号的直接转录靶基因。进行微阵列分析和通过抑制剂干扰细胞迁移的实验,以鉴定下游信号系统。
从结直肠癌(CRC)转移特征签名中鉴定出三个新基因,BOP1、CKS2 和 NFIL3,它们是β-catenin/TCF4 的直接转录靶基因。CRC 细胞中这些基因的过表达和敲低分别促进和抑制了小鼠中的实验性转移、EMT 和细胞迁移。通过 PI3K、JNK、p38 丝裂原激活蛋白激酶和/或 mTOR 抑制剂干扰不同的信号系统,可抑制细胞迁移。基因表达谱分析确定了一系列促进迁移的基因,这些基因可被 BOP1、CKS2 和 NFIL3 诱导,并且可被针对这些途径的抑制剂抑制。
我们鉴定出三个新的直接 Wnt/β-catenin 靶基因 BOP1、CKS2 和 NFIL3,它们诱导 CRC 细胞的 EMT、细胞迁移和实验性转移。这些基因与不同的下游信号系统相互作用,并激活促进迁移的基因。这些途径和下游基因可能作为 CRC 转移治疗的靶点。